Maxim Group Reiterates $24.00 Price Target for Omeros (OMER)

Maxim Group set a $24.00 price target on Omeros (NASDAQ:OMER) in a research report report published on Wednesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also weighed in on OMER. HC Wainwright set a $30.00 target price on shares of Omeros and gave the company a buy rating in a report on Thursday, December 14th. Zacks Investment Research upgraded shares of Omeros from a hold rating to a strong-buy rating and set a $22.00 target price on the stock in a report on Thursday, October 19th. Wedbush reiterated an outperform rating and issued a $47.00 target price on shares of Omeros in a report on Tuesday, November 28th. Finally, Cowen lowered shares of Omeros from an outperform rating to a market perform rating in a report on Thursday, November 2nd. Five analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Omeros has a consensus rating of Buy and an average price target of $34.14.

Omeros (NASDAQ:OMER) opened at $19.42 on Wednesday. The company has a quick ratio of 4.74, a current ratio of 4.77 and a debt-to-equity ratio of 8.99. The firm has a market cap of $945.67, a PE ratio of -15.17 and a beta of 3.56. Omeros has a fifty-two week low of $8.71 and a fifty-two week high of $27.09.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.18. The firm had revenue of $21.66 million during the quarter, compared to analyst estimates of $17.82 million. The business’s revenue for the quarter was up 91.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.34) earnings per share. equities research analysts predict that Omeros will post -0.98 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of OMER. First Interstate Bank acquired a new position in shares of Omeros in the 3rd quarter worth approximately $108,000. Legal & General Group Plc increased its stake in Omeros by 7.8% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 751 shares during the period. Hanseatic Management Services Inc. increased its stake in Omeros by 10,919.6% during the 3rd quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 10,592 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new stake in Omeros during the 3rd quarter worth approximately $256,000. Finally, SG Americas Securities LLC increased its stake in Omeros by 138.9% during the 3rd quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 7,067 shares during the period. Hedge funds and other institutional investors own 49.71% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.com-unik.info/2018/01/06/maxim-group-reiterates-24-00-price-target-for-omeros-omer.html.

Omeros Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros (NASDAQ:OMER)

What are top analysts saying about Omeros? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Omeros and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit